Gilpin Wealth Management LLC Invests $609,000 in Stryker Corporation $SYK

Gilpin Wealth Management LLC purchased a new position in Stryker Corporation (NYSE:SYK) during the 4th quarter, HoldingsChannel reports. The fund purchased 1,732 shares of the medical technology company’s stock, valued at approximately $609,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of SYK. Brighton Jones LLC lifted its stake in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares in the last quarter. Schnieders Capital Management LLC. purchased a new position in shares of Stryker in the second quarter worth about $205,000. Marshall Wace LLP increased its position in Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after purchasing an additional 77,831 shares during the last quarter. Nebula Research & Development LLC acquired a new stake in Stryker during the second quarter worth about $219,000. Finally, HUB Investment Partners LLC acquired a new stake in Stryker during the second quarter worth about $253,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Price Performance

Shares of SYK opened at $308.50 on Thursday. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The stock has a market cap of $118.27 billion, a PE ratio of 35.71, a P/E/G ratio of 1.98 and a beta of 0.78. The firm has a 50-day simple moving average of $317.20 and a two-hundred day simple moving average of $344.64. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts forecast that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is 40.74%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research report on Friday, May 1st. Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Leerink Partners cut their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a research report on Friday, May 1st. Finally, Citigroup cut their price objective on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $395.33.

Insider Activity at Stryker

In related news, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 323,264 shares of company stock worth $100,659,489. Corporate insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.